BioMarin Pharmaceutical snaps up Amicus Therapeutics for $4.8 billion

Just when little old Betaville thought the recent biopharmaceutical dealmaking boom might have ended BioMarin Pharmaceutical pops up with a $4.8 billion takeover of Amicus Therapeutics, a US-listed rare metabolic disease drug developer.

You need to register and sign in to read this content.